Neurogene Inc.
About Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$90.4M
- Total assets
- $288.6M
- Market cap
- $418.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $103.3M
- Operating income
- -$103.3M
- Income tax
- $0
- Net income
- -$90.4M
- EPS (basic)
- $-4.24
- EPS (diluted)
- $-4.24
Balance sheet
- Total assets
- $288.6M
- Current assets
- $271.8M
- Total liabilities
- $23.7M
- Current liabilities
- $16.4M
- Shareholders’ equity
- $264.9M
Cash flow
- Operating cash flow
- -$77.2M
- Investing cash flow
- $14.0M
- Financing cash flow
- $30.4M
- Net cash flow
- -$32.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $418.6M
- EPS (diluted)
- $-4.24
- Shares outstanding
- 14.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 19, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $90.4M in FY2025.
- Trading 19% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Neurogene Inc..
